Abstract:Background Atrial fibrillation (AF) and heart failure (HF) are intertwined conditions with high mortality rates and large impact on quality of life, and their coexistence is increasingly prevalent. Both conditions influence each other's development and progression, and share many risk-factors—such as hypertension, obesity, diabetes mellitus and ischaemic heart disease. Moreover, their combined presence further increases the risk of hospitalization and mortality. The biological mechanisms at play in HF patients with AF may therefore differ from those in HF patients without AF. Purpose We aimed to describe the differences in pathophysiological pathways in HF patients with versus without AF, by identifying biomarkers associated with AF from a panel of 4210 circulating proteins and subsequently examining biological mechanisms related to these biomarkers. Methods We examined 377 ambulant HF patients with reduced ejection fraction from a longitudinal cohort study. We measured 4210 circulating proteins in baseline blood samples using an aptamer-based multiplex proteomic approach. Associations between AF (known AF history or AF on the baseline ECG) and the proteins were assessed using linear regression models adjusted for age, sex, kidney function and duration of HF at baseline. Associations of proteins significantly related to AF, with biological processes, were assessed using network-based clustering and subsequent enrichment analysis. Results The median [25th, 75th percentile] age was 64 [55, 72], 73% [274/377] were male, 28% [104/375] had NYHA-class III or IV, and 37% [139/377] had AF (either AF history: 36% [137/377] or AF on baseline ECG: 8% [30/374]). We found 71 proteins significantly associated with AF (FDR<0.05), including well-studied (e.g. troponin T, IGFBP7, MFAP4, BMP10, angiopoietin 2) and lesser studied (e.g. olfactomedin−like protein 3, keratocan, basigin) proteins in the AF domain. Our pathway analysis revealed clusters of proteins related to various underlying mechanisms, such as axon guidance, elastic fibre assembly, macrophage derived foam cell differentiation, ether lipid metabolism and amyloid-beta binding. Overviews of the significantly associated proteins and related biological mechanisms are provided in Figures 1 and 2. Conclusion HF patients with AF have distinct proteomic profiles and these differences are related to various biological mechanisms, many of which can be associated with atrial remodelling. This study provides an overview of the biological mechanisms behind AF in HF, confirms prior findings regarding AF-related proteins, and could guide future research in novel treatment targets and HF-AF management.Figure 1:Proteins associated with AFFigure 2:Biological mechanisms

Metabolomics and Biomarkers for Paroxysmal and Persistent Atrial Fibrillation.

Comprehensive Metabolomic Characterization of Atrial Fibrillation

Comprehensive metabolomic and proteomic analyses reveal candidate biomarkers and related metabolic networks in atrial fibrillation.

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation

Proteomic profiles of patients with atrial fibrillation provide candidate biomarkers for diagnosis

Abstract 4142984: Sex Differences in Atrial Fibrillation: Insights from Metabolomics and Transcriptomics

Combined Metabolomic and Proteomic Analysis of Human Atrial Fibrillation

Combinational Biomarkers for Atrial Fibrillation Derived from Atrial Appendage and Plasma Metabolomics Analysis

Protomic Profiles of Patients with Atrial Fibrillation Provide New Candidate Biomakers for Diagnosis

Integrated Untargeted/targeted Metabolomics Identifies a Putative Oxylipin Signature in Patients with Atrial Fibrillation and Coronary Heart Disease

A Primary Study of Serum Metabonomic in Patients with Paroxysmal Atrial Fibrillation

How can proteomics be incorporated into the management of atrial fibrillation?

Dynamic biomarker profiles in patients with paroxysmal atrial fibrillation: Assessing the differences between sinus rhythm and acute atrial fibrillation episode

Multiple targets related to mitochondrial function unveiled by metabolomics and proteomics profiles of hearts from atrial fibrillation patients

Proteomic Analysis Of Atrial Appendages Revealed The Pathophysiological Changes Of Atrial Fibrillation

Biomarkers and key pathways in atrial fibrillation associated with mitral valve disease identified by multi-omics study

An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions

Proteomic biomarkers and biological mechanisms associated with atrial fibrillation in heart failure patients

Quantitative Proteomic Analysis to Identify Differentially Expressed Proteins in the Persistent Atrial Fibrillation Using TMT Coupled with Nano-Lc-ms/ms

Label-free Proteomic Analysis of Serum Exosomes from Paroxysmal Atrial Fibrillation Patients

Identification of Microrna Biomarkers in Atrial Fibrillation